Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Rapid Influenza Diagnostic Test (RIDT) Market by End User (Hospitals and Clinics, Laboratories, Other): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03779

Pages: NA

Charts: NA

Tables: NA

Rapid influenza diagnostic tests (RIDTs) are immunoassays which enable the identification of the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens. The RIDTs have gained traction over the years owing to the advantages offered by these tests such as quick access to the result in less than approximately 15 minutes, and is easy to perform.

The RIDTs are highly utilized in the clinical decision making as the assist in the diagnostic and treatment decisions for patients in clinical settings. The factors that fuel the growth of the global rapid influenza diagnostic tests (RIDTs) market are escalating incidence of influenza, increasing focus in research funding for influenza diagnostics, and rising demand for rapid diagnosis and control of influenza. However, variability in sensitivity as well as specificity among influenza diagnostic tests, along with unstable regulatory framework regrading approval of new diagnostic tests restrain the market growth. Moreover, emerging advanced influenza diagnostics tests in the market is anticipated to offer lucrative opportunities for the expansion of the market.

The market is segmented on the basis of end user, and region. Based on end user, the market is segmented into hospitals & clinics, laboratories, and other. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players that operate in the market are Thermo Fisher Scientific, Roche Diagnostics, Alere Inc., Quidel Corporation, Becton, Dickinson and Company, DiaSorin, SA Scientific Ltd., Meridian Bioscience, Inc., Analytik Jena AG (Endress+Hauser AG), and Luminex Corporation.

Key Benefits

  • The study provides an in-depth analysis of the global RIDTs market with current trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on prevailing market opportunities.
  • Key players have been profiled and their strategies thoroughly analyzed, which predicts the competitive outlook of the market.
  • By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Rapid Influenza Diagnostic Test (RIDT) Market Key Segments:

By End User

  • Hospitals & Clinics
  • Laboratories
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Argentina
    • Rest of LAMEA

 Key Market Segments

  • By End User
    • Hospitals and Clinics
    • Laboratories
    • Other
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Analytik Jena AG
  • Luminex Corporation
  • DiaSorin
  • Thermo Fisher Scientific Inc.
  • Quidel Corporation
  • Alere Inc.
  • Roche Diagnostics
  • Becton, Dickinson and Company
  • Meridian Bioscience, Inc.
  • SA Scientific Ltd.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET, BY END USER

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By End User

    • 4.2. Hospitals And Clinics

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Laboratories

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Other

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By End User

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Rapid Influenza Diagnostic Test (ridt) Market

        • 5.2.4.1. Market Size and Forecast, By End User

      • 5.2.5. Canada Rapid Influenza Diagnostic Test (ridt) Market

        • 5.2.5.1. Market Size and Forecast, By End User

      • 5.2.6. Mexico Rapid Influenza Diagnostic Test (ridt) Market

        • 5.2.6.1. Market Size and Forecast, By End User

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By End User

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Rapid Influenza Diagnostic Test (ridt) Market

        • 5.3.4.1. Market Size and Forecast, By End User

      • 5.3.5. Germany Rapid Influenza Diagnostic Test (ridt) Market

        • 5.3.5.1. Market Size and Forecast, By End User

      • 5.3.6. Italy Rapid Influenza Diagnostic Test (ridt) Market

        • 5.3.6.1. Market Size and Forecast, By End User

      • 5.3.7. Spain Rapid Influenza Diagnostic Test (ridt) Market

        • 5.3.7.1. Market Size and Forecast, By End User

      • 5.3.8. UK Rapid Influenza Diagnostic Test (ridt) Market

        • 5.3.8.1. Market Size and Forecast, By End User

      • 5.3.9. Russia Rapid Influenza Diagnostic Test (ridt) Market

        • 5.3.9.1. Market Size and Forecast, By End User

      • 5.3.10. Rest Of Europe Rapid Influenza Diagnostic Test (ridt) Market

        • 5.3.10.1. Market Size and Forecast, By End User

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By End User

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.4.1. Market Size and Forecast, By End User

      • 5.4.5. Japan Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.5.1. Market Size and Forecast, By End User

      • 5.4.6. India Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.6.1. Market Size and Forecast, By End User

      • 5.4.7. South Korea Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.7.1. Market Size and Forecast, By End User

      • 5.4.8. Australia Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.8.1. Market Size and Forecast, By End User

      • 5.4.9. Thailand Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.9.1. Market Size and Forecast, By End User

      • 5.4.10. Malaysia Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.10.1. Market Size and Forecast, By End User

      • 5.4.11. Indonesia Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.11.1. Market Size and Forecast, By End User

      • 5.4.12. Rest of Asia Pacific Rapid Influenza Diagnostic Test (ridt) Market

        • 5.4.12.1. Market Size and Forecast, By End User

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By End User

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Rapid Influenza Diagnostic Test (ridt) Market

        • 5.5.4.1. Market Size and Forecast, By End User

      • 5.5.5. South Africa Rapid Influenza Diagnostic Test (ridt) Market

        • 5.5.5.1. Market Size and Forecast, By End User

      • 5.5.6. Saudi Arabia Rapid Influenza Diagnostic Test (ridt) Market

        • 5.5.6.1. Market Size and Forecast, By End User

      • 5.5.7. UAE Rapid Influenza Diagnostic Test (ridt) Market

        • 5.5.7.1. Market Size and Forecast, By End User

      • 5.5.8. Argentina Rapid Influenza Diagnostic Test (ridt) Market

        • 5.5.8.1. Market Size and Forecast, By End User

      • 5.5.9. Rest of LAMEA Rapid Influenza Diagnostic Test (ridt) Market

        • 5.5.9.1. Market Size and Forecast, By End User

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning, 2024

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. Thermo Fisher Scientific Inc.

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Roche Diagnostics

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Alere Inc.

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Quidel Corporation

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Becton, Dickinson And Company

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. DiaSorin

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. SA Scientific Ltd.

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Meridian Bioscience, Inc.

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Analytik Jena AG

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. Luminex Corporation

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET FOR LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET FOR OTHER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. NORTH AMERICA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. NORTH AMERICA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 8. U.S. RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 9. CANADA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 10. MEXICO RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 11. EUROPE RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. EUROPE RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 13. FRANCE RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 14. GERMANY RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. ITALY RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 16. SPAIN RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. UK RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. RUSSIA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. REST OF EUROPE RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. ASIA-PACIFIC RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. ASIA-PACIFIC RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. CHINA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. JAPAN RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. INDIA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. SOUTH KOREA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. AUSTRALIA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. THAILAND RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. MALAYSIA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. INDONESIA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. REST OF ASIA PACIFIC RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. LAMEA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY REGION, 2025-2033 ($MILLION)
  • TABLE 32. LAMEA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. BRAZIL RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. SOUTH AFRICA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. SAUDI ARABIA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. UAE RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. ARGENTINA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. REST OF LAMEA RAPID INFLUENZA DIAGNOSTIC TEST (RIDT), BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 40. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 41. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 42. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 43. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 44. ROCHE DIAGNOSTICS: KEY EXECUTIVES
  • TABLE 45. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 46. ROCHE DIAGNOSTICS: OPERATING SEGMENTS
  • TABLE 47. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 48. ROCHE DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 49. ALERE INC.: KEY EXECUTIVES
  • TABLE 50. ALERE INC.: COMPANY SNAPSHOT
  • TABLE 51. ALERE INC.: OPERATING SEGMENTS
  • TABLE 52. ALERE INC.: PRODUCT PORTFOLIO
  • TABLE 53. ALERE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 54. QUIDEL CORPORATION: KEY EXECUTIVES
  • TABLE 55. QUIDEL CORPORATION: COMPANY SNAPSHOT
  • TABLE 56. QUIDEL CORPORATION: OPERATING SEGMENTS
  • TABLE 57. QUIDEL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 58. QUIDEL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 59. BECTON, DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 60. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 61. BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS
  • TABLE 62. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 63. BECTON, DICKINSON AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 64. DIASORIN: KEY EXECUTIVES
  • TABLE 65. DIASORIN: COMPANY SNAPSHOT
  • TABLE 66. DIASORIN: OPERATING SEGMENTS
  • TABLE 67. DIASORIN: PRODUCT PORTFOLIO
  • TABLE 68. DIASORIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 69. SA SCIENTIFIC LTD.: KEY EXECUTIVES
  • TABLE 70. SA SCIENTIFIC LTD.: COMPANY SNAPSHOT
  • TABLE 71. SA SCIENTIFIC LTD.: OPERATING SEGMENTS
  • TABLE 72. SA SCIENTIFIC LTD.: PRODUCT PORTFOLIO
  • TABLE 73. SA SCIENTIFIC LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 74. MERIDIAN BIOSCIENCE, INC.: KEY EXECUTIVES
  • TABLE 75. MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT
  • TABLE 76. MERIDIAN BIOSCIENCE, INC.: OPERATING SEGMENTS
  • TABLE 77. MERIDIAN BIOSCIENCE, INC.: PRODUCT PORTFOLIO
  • TABLE 78. MERIDIAN BIOSCIENCE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. ANALYTIK JENA AG: KEY EXECUTIVES
  • TABLE 80. ANALYTIK JENA AG: COMPANY SNAPSHOT
  • TABLE 81. ANALYTIK JENA AG: OPERATING SEGMENTS
  • TABLE 82. ANALYTIK JENA AG: PRODUCT PORTFOLIO
  • TABLE 83. ANALYTIK JENA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. LUMINEX CORPORATION: KEY EXECUTIVES
  • TABLE 85. LUMINEX CORPORATION: COMPANY SNAPSHOT
  • TABLE 86. LUMINEX CORPORATION: OPERATING SEGMENTS
  • TABLE 87. LUMINEX CORPORATION: PRODUCT PORTFOLIO
  • TABLE 88. LUMINEX CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET SEGMENTATION
  • FIGURE 2. GLOBAL RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET
  • FIGURE 3. SEGMENTATION RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALRAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET
  • FIGURE 11. RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET SEGMENTATION, BY BY END USER
  • FIGURE 12. RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET FOR LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET FOR OTHER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 16. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 17. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 18. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 19. COMPETITIVE DASHBOARD
  • FIGURE 20. COMPETITIVE HEATMAP: RAPID INFLUENZA DIAGNOSTIC TEST (RIDT) MARKET
  • FIGURE 21. TOP PLAYER POSITIONING, 2024
  • FIGURE 22. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 23. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 24. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 25. ROCHE DIAGNOSTICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 26. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 27. ROCHE DIAGNOSTICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 28. ALERE INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. ALERE INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. ALERE INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. QUIDEL CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. QUIDEL CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. QUIDEL CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. BECTON, DICKINSON AND COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. BECTON, DICKINSON AND COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. BECTON, DICKINSON AND COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. DIASORIN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. DIASORIN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. DIASORIN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. SA SCIENTIFIC LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. SA SCIENTIFIC LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. SA SCIENTIFIC LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. MERIDIAN BIOSCIENCE, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. MERIDIAN BIOSCIENCE, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. MERIDIAN BIOSCIENCE, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. ANALYTIK JENA AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. ANALYTIK JENA AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. ANALYTIK JENA AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. LUMINEX CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. LUMINEX CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. LUMINEX CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Rapid Influenza Diagnostic Test (RIDT) Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved